Начало・Списък с акции・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Отворен

СекторЗдравеопазване

38.21 -1.39

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

38.04

Максимум

39.36

Ключови измерители
By Trading Economics
Приходи	10M 32M
Продажби	-28M 215M
P/E Средно за сектора	14.355 68.51
EPS	0.79
Марж на печалбата	15.084
Служители	293
EBITDA	-2.8M 49M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+7.43% upside

Дивиденти
By Acuity
Следващи печалби	3.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	175M 2.1B
Предишно отваряне	39.6
Предишно затваряне	38.21

Настроения в новините

By Acuity

10%

90%

14 / 340 Класиране в Healthcare

Harmony Biosciences Holdings Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.08.2026 г., 23:51 ч. UTC

Harmony Biosciences Holdings Inc shares declined during after-market hours, struggling to maintain earlier gains amid a lack of specific news to explain the movement.

5.08.2026 г., 20:03 ч. UTC

Social Media

Event

News

Harmony Biosciences shares are lower despite new Phase 1 data on BP-205. Truist maintains a Hold rating and raises the price target to $34.

4.08.2026 г., 20:04 ч. UTC

Social Media

News

Event

Harmony Biosciences reported strong Q2 earnings of $75.43 million and reaffirmed 2026 revenue guidance, with shares trading sharply higher during the session.

3.08.2026 г., 23:11 ч. UTC

Harmony Biosciences shares are higher in after-hours trading, supported by positive sentiment from the Institute for Supply Management's manufacturing PMI report.

1.08.2026 г., 00:01 ч. UTC

Shares of Harmony Biosciences Holdings Inc are higher in after-market trading, reflecting notable strength since Friday's close without any specific news driving the move.

31.07.2026 г., 23:21 ч. UTC

Harmony Biosciences Holdings Inc. is trading higher during after-market hours, reflecting steady price increases since Friday's close, despite no specific news identified.

28.07.2026 г., 18:26 ч. UTC

News

Shares of Harmony Biosciences are lower despite a 30% revenue increase for WAKIX, as market sentiment reflects concerns over potential cash flow erosion.

27.07.2026 г., 19:41 ч. UTC

Shares of Harmony Biosciences Holdings Inc. are higher today, breaking from a recent upward trend despite the absence of specific company news.

24.07.2026 г., 17:06 ч. UTC

Shares of Harmony Biosciences Holdings Inc. are lower today, continuing a decline since Thursday's close, despite earlier reaching a session high.

22.07.2026 г., 20:01 ч. UTC

News

Harmony Biosciences Holdings Inc is trading lower despite preliminary Q2 2026 results showing record net product revenue of approximately $261 million, a 30% year-over-year increase.

21.07.2026 г., 21:01 ч. UTC

Harmony Biosciences Holdings Inc. shares are lower in after-market trading, diverging from a broader market rebound despite no specific news driving the decline.

Сравнение с други в отрасъла

Ценова промяна

Harmony Biosciences Holdings Inc Прогноза

Ценова цел

By TipRanks

7.43% нагоре

12-месечна прогноза

Среден 41.63 USD 7.43%

Висок 55 USD

Нисък 30 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Harmony Biosciences Holdings Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Harmony Biosciences Holdings Inc през последните 3 месеца.

Настроение

By Acuity

14 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.